Published in Gene Therapy Weekly, June 10th, 1996
Under the collaboration, Chiron selects gene sequences and RPI designs and synthesizes ribozymes that selectively inhibit the action of the target sequences in Chiron's assays. Chiron has the option to develop ribozymes or other products against sequences found to be important in disease pathology. RPI receives research support, milestone payments, royalties and ribozyme manufacturing rights on products resulting from the collaboration.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.